Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UCHL1 | P09936 | 2/20 | 0.52 |
| ▸ | USP30 | Q70CQ3 | 7/20 | 0.50 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.48 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | HPGDS | O60760 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29377780 | 1.00 | UCHL1 (0.52) | UCHL1USP30MKNK1PDE10AKDR | |
| SCHEMBL22494665 | 1.00 | UCHL1 (0.52) | UCHL1USP30MKNK1PDE10AKDR | |
| SCHEMBL22494673 | 0.89 | UCHL1 (0.63) | UCHL1USP30MKNK1KDRGSTO1 | |
| SCHEMBL22494615 | 0.89 | UCHL1 (0.63) | UCHL1USP30MKNK1KDRGSTO1 | |
| SCHEMBL22494614 | 0.89 | UCHL1 (0.63) | UCHL1USP30MKNK1KDRGSTO1 | |
| SCHEMBL22494806 | 0.82 | UCHL1 (0.62) | UCHL1USP30MKNK1KDRGSTO1 | |
| SCHEMBL29146009 | 0.82 | UCHL1 (0.62) | UCHL1USP30MKNK1KDRGSTO1 | |
| SCHEMBL20883072 | 0.82 | UCHL1 (0.62) | UCHL1USP30MKNK1KDRGSTO1 | |
| SCHEMBL20883074 | 0.82 | UCHL1 (0.62) | UCHL1USP30MKNK1KDRGSTO1 | |
| SCHEMBL17632444 | 0.80 | UCHL1 (0.81) | UCHL1USP30MKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3692028-B1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 | FORMA THERAPEUTICS INC (US) | 2023-04-26 | — | — | EP | claimed |
| US-11247987-B2 | Inhibiting ubiquitin specific peptidase 30 | FORMA THERAPEUTICS, INC. (US) | 2022-02-15 | — | — | US | claimed |
| EP-3692028-B1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 | FORMA THERAPEUTICS INC (US) | 2023-04-26 | — | — | EP | disclosed |
| US-20220185806-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 | FORMA THERAPEUTICS, INC. | 2022-06-16 | — | — | US | disclosed |
| US-20220185806-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 | FORMA THERAPEUTICS, INC. | 2022-06-16 | — | — | US | disclosed |
| US-11247987-B2 | Inhibiting ubiquitin specific peptidase 30 | FORMA THERAPEUTICS, INC. (US) | 2022-02-15 | — | — | US | disclosed |
| US-11247987-B2 | Inhibiting ubiquitin specific peptidase 30 | FORMA THERAPEUTICS, INC. (US) | 2022-02-15 | — | — | US | disclosed |
| US-20200317658-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 | FORMA THERAPEUTICS, INC. | 2020-10-08 | — | — | US | disclosed |
| US-20200317658-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 | FORMA THERAPEUTICS, INC. | 2020-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220185806-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 | USP30, UCHL1, UCHL3 | UCHL1 2/4885USP30 1/4885MKNK1 1080/4885 |
| US-11247987-B2 | Inhibiting ubiquitin specific peptidase 30 | USP30, UCHL1, UCHL3 | UCHL1 2/4885USP30 1/4885MKNK1 2208/4885 |
| US-20200317658-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 | USP30, UCHL1, UCHL3 | UCHL1 2/4885USP30 1/4885MKNK1 1080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.